|
IL117923A
(en)
*
|
1995-05-03 |
2000-06-01 |
Warner Lambert Co |
Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
|
|
US5620981A
(en)
*
|
1995-05-03 |
1997-04-15 |
Warner-Lambert Company |
Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
|
|
EP0912559B1
(en)
|
1996-07-13 |
2002-11-06 |
Glaxo Group Limited |
Fused heterocyclic compounds as protein tyrosine kinase inhibitors
|
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
|
US6498163B1
(en)
|
1997-02-05 |
2002-12-24 |
Warner-Lambert Company |
Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
|
|
EP1806348A3
(en)
*
|
1997-02-05 |
2008-01-02 |
Warner-Lambert Company LLC |
Pyrido [2, 3 -d] pyrimidines and 4-amino-primidines as inhibitors of cellular proliferation
|
|
KR20000070751A
(ko)
*
|
1997-02-05 |
2000-11-25 |
로즈 암스트롱, 크리스틴 에이. 트러트웨인 |
세포 증식 억제제로서의 피리도[2,3-ｄ]피리미딘 및 4-아미노피리미딘
|
|
JP4965021B2
(ja)
*
|
1997-08-20 |
2012-07-04 |
ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー |
プロテインチロシンキナーゼおよび細胞周期キナーゼ仲介細胞増殖を阻害するためのナフチリジノン
|
|
KR20010043829A
(ko)
|
1998-05-26 |
2001-05-25 |
로즈 암스트롱, 크리스틴 에이. 트러트웨인 |
세포 증식 억제제로서의 비시클릭 피리미딘 및 비시클릭3,4-디히드로피리미딘
|
|
EP1801112A1
(en)
*
|
1998-05-26 |
2007-06-27 |
Warner-Lambert Company LLC |
Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
|
|
GB9822450D0
(en)
*
|
1998-10-14 |
1998-12-09 |
Smithkline Beecham Plc |
Medicaments
|
|
GB9914486D0
(en)
|
1999-06-21 |
1999-08-18 |
Smithkline Beecham Plc |
Medicaments
|
|
GB9917408D0
(en)
|
1999-07-23 |
1999-09-22 |
Smithkline Beecham Plc |
Compounds
|
|
GB9917406D0
(en)
|
1999-07-23 |
1999-09-22 |
Smithkline Beecham Plc |
Compounds
|
|
US7053070B2
(en)
*
|
2000-01-25 |
2006-05-30 |
Warner-Lambert Company |
Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
|
|
PE20011066A1
(es)
*
|
2000-01-25 |
2001-10-22 |
Warner Lambert Co |
PIRIDO [2,3-d] PIRIMIDIN-2,7-DIAMINAS INHIBIDORES DE CINASAS
|
|
NZ523749A
(en)
|
2000-07-26 |
2005-03-24 |
Smithkline Beecham P |
Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
|
|
US6506749B2
(en)
|
2000-08-31 |
2003-01-14 |
Syntex (U.S.A.) Llc |
7-oxo-pyridopyrimidines (I)
|
|
US6518276B2
(en)
*
|
2000-08-31 |
2003-02-11 |
Syntex (U.S.A.) Llc |
7-oxo-pyridopyrimidines (II)
|
|
AU2001293784B2
(en)
*
|
2000-08-31 |
2007-08-30 |
F. Hoffmann-La Roche Ag |
7-OXO pyridopyrimidines as inhibitors of a cellular proliferation
|
|
US20020119148A1
(en)
*
|
2000-09-01 |
2002-08-29 |
Gerritsen Mary E. |
ErbB4 antagonists
|
|
DE60209886T2
(de)
|
2001-01-19 |
2006-10-26 |
Smithkline Beecham Corp. |
Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
|
|
GB0101577D0
(en)
|
2001-01-22 |
2001-03-07 |
Smithkline Beecham Plc |
Compounds
|
|
CN100376571C
(zh)
|
2001-02-12 |
2008-03-26 |
霍夫曼-拉罗奇有限公司 |
6-取代的吡啶并嘧啶类化合物
|
|
WO2002090360A1
(en)
*
|
2001-05-10 |
2002-11-14 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
|
GB0112836D0
(en)
|
2001-05-25 |
2001-07-18 |
Smithkline Beecham Plc |
Medicaments
|
|
GB0112834D0
(en)
|
2001-05-25 |
2001-07-18 |
Smithkline Beecham Plc |
Medicaments
|
|
WO2003000011A2
(en)
*
|
2001-06-21 |
2003-01-03 |
Ariad Pharmaceuticals, Inc. |
Novel pyridopyrimidines and uses thereof
|
|
ES2251677T3
(es)
|
2002-01-22 |
2006-05-01 |
Warner-Lambert Company Llc |
2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas.
|
|
EP1470125A1
(en)
|
2002-01-29 |
2004-10-27 |
Glaxo Group Limited |
Aminopiperidine derivatives
|
|
JP4508650B2
(ja)
|
2002-01-29 |
2010-07-21 |
グラクソ グループ リミテッド |
アミノピペリジン化合物、当該化合物の製法および当該化合物を含有する医薬組成物
|
|
EP1481678A4
(en)
*
|
2002-03-05 |
2009-12-30 |
Eisai R&D Man Co Ltd |
ANTITUMORAL AGENT CONTAINING A SULFONAMIDE-CONTAINING HETEROCYCLIC COMPOUND AND AN ANGIOGENESIS INHIBITOR
|
|
PA8577501A1
(es)
|
2002-07-25 |
2004-02-07 |
Warner Lambert Co |
Inhibidores de quinasas
|
|
CA2492112A1
(en)
|
2002-08-06 |
2004-02-19 |
F. Hoffmann-La Roche Ag |
6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors
|
|
US7098332B2
(en)
*
|
2002-12-20 |
2006-08-29 |
Hoffmann-La Roche Inc. |
5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
|
|
TW200502236A
(en)
*
|
2003-03-28 |
2005-01-16 |
Hoffmann La Roche |
Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
|
|
RU2263146C2
(ru)
*
|
2003-07-10 |
2005-10-27 |
Михаил Викторович Разуменко |
Способ получения бактериофагов, специфично связывающихся с клетками-мишенями и предназначенных для терапевтических целей
|
|
ATE412650T1
(de)
*
|
2003-07-11 |
2008-11-15 |
Warner Lambert Co |
Isethionat salz eines selektiven cdk4 inhibitors
|
|
JP4616839B2
(ja)
|
2003-11-13 |
2011-01-19 |
エフ．ホフマン−ラ ロシュ アーゲー |
ヒドロキシアルキル置換ピリド−７−ピリミジン−７−オン類
|
|
EP2260849A1
(en)
|
2004-01-21 |
2010-12-15 |
Emory University |
Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection
|
|
US7189732B2
(en)
|
2004-03-15 |
2007-03-13 |
Hoffman-La Roche Inc. |
Pyrido[2,3-d]pyrimidine dichloro-phenyl derivatives
|
|
FR2873118B1
(fr)
|
2004-07-15 |
2007-11-23 |
Sanofi Synthelabo |
Derives de pyrido-pyrimidine, leur application en therapeutique
|
|
EP1794160A1
(en)
*
|
2004-09-21 |
2007-06-13 |
F.Hoffmann-La Roche Ag |
6-(2-alkyl-phenyl) - pyrido[2,3-d] pyrimidines useful as proteine kinase inhibitors
|
|
US20070054916A1
(en)
|
2004-10-01 |
2007-03-08 |
Amgen Inc. |
Aryl nitrogen-containing bicyclic compounds and methods of use
|
|
EP1838296B1
(en)
*
|
2004-10-20 |
2012-08-08 |
Resverlogix Corp. |
Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
|
|
US20080207677A1
(en)
*
|
2004-12-31 |
2008-08-28 |
Gpc Biotech Ag |
Napthyridine Compounds As Rock Inhibitors
|
|
FR2887882B1
(fr)
*
|
2005-07-01 |
2007-09-07 |
Sanofi Aventis Sa |
Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
|
|
US8410109B2
(en)
|
2005-07-29 |
2013-04-02 |
Resverlogix Corp. |
Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
|
|
BRPI0614804A2
(pt)
*
|
2005-08-09 |
2011-04-12 |
Irm Llc |
compostos e composições como inibidores de proteìna cinase
|
|
US20070082920A1
(en)
*
|
2005-10-06 |
2007-04-12 |
Yongsheng Song |
NAD+-dependent DNA ligase inhibitors
|
|
RU2445315C2
(ru)
*
|
2005-11-22 |
2012-03-20 |
Кудос Фармасьютиклз Лимитед |
ПРОИЗВОДНЫЕ ПИРИДО-, ПИРАЗО- И ПИРИМИДО-ПИРИМИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ mTOR
|
|
FR2896246B1
(fr)
|
2006-01-13 |
2008-08-15 |
Sanofi Aventis Sa |
Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
|
|
EP1981886B1
(en)
|
2006-01-31 |
2009-08-12 |
F.Hoffmann-La Roche Ag |
7h-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors
|
|
WO2008032162A1
(en)
|
2006-09-15 |
2008-03-20 |
Pfizer Products Inc. |
Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
|
|
CA2668731A1
(en)
*
|
2006-11-09 |
2008-05-15 |
Tobias Gabriel |
Kinase inhibitors and methods for using the same
|
|
FR2910813B1
(fr)
|
2006-12-28 |
2009-02-06 |
Sanofi Aventis Sa |
Nouvelle utilisation therapeutique pour le traitement des leucemies
|
|
AU2007345526B2
(en)
|
2007-02-01 |
2013-02-28 |
Resverlogix Corp. |
Compounds for the prevention and treatment of cardiovascular diseases
|
|
WO2008104473A2
(en)
*
|
2007-02-28 |
2008-09-04 |
F. Hoffmann-La Roche Ag |
Pyrazolopyriidine derivatives and their use as kinase inhibitors
|
|
US20090203709A1
(en)
*
|
2008-02-07 |
2009-08-13 |
Abbott Laboratories |
Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
|
|
US8110578B2
(en)
*
|
2008-10-27 |
2012-02-07 |
Signal Pharmaceuticals, Llc |
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
|
|
AU2010204106B2
(en)
|
2009-01-08 |
2014-05-08 |
Resverlogix Corp. |
Compounds for the prevention and treatment of cardiovascular disease
|
|
MX392179B
(es)
|
2009-03-18 |
2025-03-21 |
Resverlogix Corp |
Nuevos agentes anti-inflamatorios.
|
|
TR201818390T4
(tr)
|
2009-04-22 |
2019-01-21 |
Resverlogix Corp |
Yeni̇ anti̇-i̇nflamatuvar ajanlar
|
|
ES2347630B1
(es)
*
|
2009-04-29 |
2011-09-08 |
Universitat Ramon Llull |
Sintesis y usos de 4-cianopentanoatos y 4-cianopentenoatos sustituidos.
|
|
GB0922589D0
(en)
*
|
2009-12-23 |
2010-02-10 |
Almac Discovery Ltd |
Pharmaceutical compounds
|
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
|
ES2745471T3
(es)
|
2011-11-01 |
2020-03-02 |
Resverlogix Corp |
Formulaciones orales de liberación inmediata para quinazolinonas sustituidas
|
|
CN107652289B
(zh)
|
2012-06-13 |
2020-07-21 |
因塞特控股公司 |
作为fgfr抑制剂的取代的三环化合物
|
|
HUE055502T2
(hu)
*
|
2012-07-11 |
2021-11-29 |
Blueprint Medicines Corp |
Fibroblaszt növekedési faktor receptor gátlók
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
GB201216018D0
(en)
|
2012-09-07 |
2012-10-24 |
Cancer Rec Tech Ltd |
Pharmacologically active compounds
|
|
GB201216017D0
(en)
|
2012-09-07 |
2012-10-24 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
|
US9765039B2
(en)
|
2012-11-21 |
2017-09-19 |
Zenith Epigenetics Ltd. |
Biaryl derivatives as bromodomain inhibitors
|
|
US9073878B2
(en)
|
2012-11-21 |
2015-07-07 |
Zenith Epigenetics Corp. |
Cyclic amines as bromodomain inhibitors
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
EP2935253B1
(en)
|
2012-12-21 |
2018-08-01 |
Zenith Epigenetics Ltd. |
Novel heterocyclic compounds as bromodomain inhibitors
|
|
TWI647220B
(zh)
|
2013-03-15 |
2019-01-11 |
美商西建卡爾有限責任公司 |
雜芳基化合物及其用途
|
|
CN111793068A
(zh)
*
|
2013-03-15 |
2020-10-20 |
西建卡尔有限责任公司 |
杂芳基化合物和其用途
|
|
KR102350704B1
(ko)
|
2013-03-15 |
2022-01-13 |
셀젠 카르 엘엘씨 |
헤테로아릴 화합물 및 이의 용도
|
|
KR102269032B1
(ko)
|
2013-04-19 |
2021-06-24 |
인사이트 홀딩스 코포레이션 |
Fgfr 저해제로서 이환식 헤테로사이클
|
|
CA2928042C
(en)
|
2013-10-25 |
2022-05-10 |
Blueprint Medicines Corporation |
Inhibitors of the fibroblast growth factor receptor
|
|
US9695165B2
(en)
|
2014-01-15 |
2017-07-04 |
Blueprint Medicines Corporation |
Inhibitors of the fibroblast growth factor receptor
|
|
GB201403536D0
(en)
|
2014-02-28 |
2014-04-16 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
PE20171514A1
(es)
|
2015-02-20 |
2017-10-20 |
Incyte Corp |
Heterociclos biciclicos como inhibidores de fgfr
|
|
KR102662814B1
(ko)
|
2015-03-13 |
2024-05-03 |
리스버로직스 코퍼레이션 |
보체 관련 질환을 치료하기 위한 조성물 및 치료 방법
|
|
CN107660200B
(zh)
*
|
2015-04-14 |
2022-01-11 |
卫材R&D管理有限公司 |
结晶fgfr4抑制剂化合物和其用途
|
|
CN104774183B
(zh)
*
|
2015-04-24 |
2017-10-13 |
合肥新诺华生物科技有限公司 |
一种甲酰基瑞舒伐汀钙中间体的制备方法
|
|
WO2018023081A1
(en)
*
|
2016-07-29 |
2018-02-01 |
Achaogen, Inc. |
6-phenylpyrido[2,3-d]pyrimidine compounds as antibacterial agents
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
GB201709840D0
(en)
|
2017-06-20 |
2017-08-02 |
Inst Of Cancer Research: Royal Cancer Hospital |
Methods and medical uses
|
|
BR112020021802A2
(pt)
|
2018-04-23 |
2021-02-23 |
Kyoto University |
métodos para produzir uma população de células produtoras de insulina ou uma população de células beta pancreáticas e para diminuir o número ou inibir a proliferação de células positivas para ki67, e, população de células progenitoras pancreáticas ou células em um estágio posterior de diferenciação
|
|
SG11202010636VA
(en)
|
2018-05-04 |
2020-11-27 |
Incyte Corp |
Solid forms of an fgfr inhibitor and processes for preparing the same
|
|
BR112020022373A2
(pt)
|
2018-05-04 |
2021-02-02 |
Incyte Corporation |
sais de um inibidor de fgfr
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
US20220389009A1
(en)
*
|
2019-10-01 |
2022-12-08 |
Goldfinch Bio, Inc. |
Substituted 1,6-naphthyridine inhibitors of cdk5
|
|
WO2021076602A1
(en)
|
2019-10-14 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
JP7720840B2
(ja)
|
2019-12-04 |
2025-08-08 |
インサイト・コーポレイション |
Ｆｇｆｒ阻害剤としての三環式複素環
|
|
CN115151539A
(zh)
|
2019-12-04 |
2022-10-04 |
因赛特公司 |
Fgfr抑制剂的衍生物
|
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
US12065494B2
(en)
|
2021-04-12 |
2024-08-20 |
Incyte Corporation |
Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
|
|
AR126102A1
(es)
|
2021-06-09 |
2023-09-13 |
Incyte Corp |
Heterociclos tricíclicos como inhibidores de fgfr
|
|
CA3220155A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|